Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 31;11:660. doi: 10.1038/s41467-019-12901-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Superior antitumor response by adoptively transferred T cells with NKTR-214 compared to IL-2. a Schematic of the pmel-1 ACT model. Time points in days throughout the text refer to the number of days post-administration of ACT + NKTR-214 or ACT + IL-2 at day 0. Subsequent to day 0, no further ACT was given. A second dose of either NKTR-214 (one dose) or IL-2 (qdx3) was given at day 9 and day 18 per the q9dx3 dosing regimen. b Changes in mean tumor volume over time. Data are means ± s.e.m (n = 12). *p < 0.0001 compared to ACT + IL-2; ^#p < 0.0001 compared to vehicle (two-way ANOVA, with Bonferroni-Dunn multiple comparisons test). (c)Tumor growth delay was assessed for each tumor growth curve by interpolating the time to achieve tumor volume of 1000 mm³. ^#p < 0.0001 compared to ACT + IL-2 (Log-Rank Mantel–Cox test). The experiment is representative of three replicates.